NEW YORK, June 09, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Shareholders have until July 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/neurotrope-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



